

2022 Annual Breast Carcinoma Result Comparison Report

Tests Performed by Summit Pathology

The following tables summarize results from tests performed and read by Summit Pathology for all clients. All tests were performed and interpreted by Summit Pathology unless noted otherwise in the summary tables.

Estrogen and Progesterone Receptor Testing

Estrogen Receptor IHC Results

	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	182	18.00%	50	17.61%	132	18.16%
Positive	829	82.00%	234	82.39%	595	81.84%

¹ Estrogen receptor negative benchmark is at or below 30%

² Women 55 and older were classified as postmenopausal.

Progesterone Receptor IHC Results

	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	334	32.94%	89	31.12%	245	33.65%
Positive	680	67.06%	197	68.88%	483	66.35%

¹ Progesterone receptor negative benchmark is 10-15% greater than estrogen receptor negative results.

² Women 55 and older were classified as postmenopausal.

Estrogen and Progesterone Receptor Negative Results: Special Types and Well-differentiated Carcinomas

Classification	Results	Estrogen Receptor Negative		Progesterone Receptor Negative	
		n	Percentage	n	Percentage
Lobular	119	4	3.36%	28	23.53%
Mucinous	14	0	0.00%	0	0.00%
Tubular	11	1	9.09%	3	27.27%
Tubulolobular	1	0	0.00%	0	0.00%
Well-differentiated	328	3	0.91%	43	13.11%

HER2/neu Testing

	All Grades		Low Grade		Intermediate Grade		High Grade	
	n	Percentage ¹	n	Percentage	n	Percentage	n	Percentage
Equivocal	1	0.15%	—	—	—	—	1	0.67%
Negative	559	86.40%	205	96.24%	237	83.16%	117	78.52%
Positive	87	13.45%	8	3.76%	48	16.84%	31	20.81%

¹ Benchmark for overall HER2/neu results is 10-25% positive.

Summary statistics represent combined IHC and amplification study results.

Additional Laboratory-wide results from HER2/neu testing in 2022

Frequency of HER2 equivocal carcinomas:

IHC scores of 2+ were found in 18.01% (268) of 1488 HER2/neu carcinomas.

Frequency of ISH positive results in HER2/neu equivocal (IHC=2+) carcinomas

10.32% (16) of 155 HER2/neu equivocal carcinomas (IHC=2+) were also ISH positive.

Frequency of HER2/neu positive carcinomas (IHC=3+)

IHC scores of 3+ were found in 9.68% (144) of 1488 HER2/neu carcinomas.

Comments by Medical Director

Medical Director : _____

Date: _____